Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has entered into a partnership with Hawkeye Bio and #EaseHealthcare to advance the development of a new blood test for the early detection of lung cancer.
The diagnostic, called the Lung Enzyme Activity Profile (LEAP), is designed as a non-invasive and radiation-free method to detect early-stage lung cancer across all subtypes. Clinical trials have shown a 99.8 percent negative predictive value, highlighting its potential to rule out the disease in high-risk groups, including older smokers, firefighters, military personnel, and first responders.
HydroGraph’s #graphene production technology enables the creation of ultra-pure material that serves as the foundation for #HawkeyeBio’s nanoscale #biosensor. This biosensor measures enzymatic activity associated with inflammatory disease, a biomarker linked to the early development of lung cancer.
“This partnership underscores the medical potential of high-purity graphene,” said Kjirstin Breure, president and CEO of #HydroGraph. “Our ability to deliver graphene at scale supports groundbreaking diagnostics like Hawkeye’s biosensors and Ease’s LEAP test, ultimately saving lives through earlier detection and intervention.”
#Lungcancer remains the leading cause of cancer-related deaths. The American Cancer Society projects approximately 227,000 new cases and nearly 125,000 deaths in the United States in 2025. Despite these figures, participation in recommended annual low-dose CT screening remains low, with only 2 to 6 percent of at-risk individuals undergoing scans.
The collaboration is intended to increase adherence to screening guidelines and expand access to affordable testing in primary care. Longer-term plans include extending the platform to address additional cancers and diseases.
source : Advanced Carbons Council

Comments
Post a Comment